Lecia V. Sequist

Lecia Sequist is an internationally recognized thoracic oncologist whose research has defined the natural history of EGFR-mutant NSCLC under selective pressure from targeted therapies. She characterized the emergence and clinical significance of the T790M resistance mutation and contributed to development of osimertinib for T790M-positive disease. Her current work focuses on early cancer detection using liquid biopsy. She has mentored numerous investigators and leads national cooperative group studies.